Date: 2018-04-30
Type of information: Nomination
Compound: member of the scientific advisory board
Company: Glythera (UK)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On April 30, 2018, Glythera, a next-generation antibody drug conjugate (ADC) development company, announced that it has appointed Professor Kerry Chester to its Scientific Advisory Board (SAB). Professor Chester’s appointment strengthens the Company’s SAB and will help shape its portfolio of ADCs for targeting previously untreatable cancers.
- Professor Chester leads the Antibody Engineering Group at University College London (UCL) Cancer Institute and has over 20 years’ experience in antibody engineering, antibody phage-display technology and bench-to-bedside antibody development, including manufacture for clinical trials. Her main research interests are design and construction of antibody-based therapeutics and the interaction of these molecules with specific cancer targets for the development of new agents for clinical use. Professor Chester is currently President of the Antibody Society.
- Professor Chester’s current projects include development of antibodies for use as ADCs, chimeric antigen receptors (CARs), nano-medicines and cancer imaging agents. Her group has established a GMP facility for manufacturing clinical-grade recombinant antibody-based cancer treatments for use in First-in-Man clinical trials. Additionally, her group designed and manufactured the first single-chain Fv (scFv) antibody to enter clinical trials.
Financial terms:
Latest news:
Is general: Yes
